TY - JOUR T1 - Ulcerative colitis: an update JF - Clinical Medicine JO - Clin Med SP - 135 LP - 139 DO - 10.7861/clinmed.2021-0080 VL - 21 IS - 2 AU - Jonathan P Segal AU - Jean-Frédéric LeBlanc AU - Ailsa L Hart Y1 - 2021/03/01 UR - http://www.rcpjournals.org/content/21/2/135.abstract N2 - Ulcerative colitis is a relapsing and remitting disease that is increasing in incidence and prevalence. Management aims to achieve rapid resolution of symptoms, mucosal healing and improvement in a patient’s quality of life. 5-aminosalicylate acid medications remain the first-line treatment for mild to moderate disease. In the event of suboptimal response to these medications, escalation to immunosuppressive medications and biologics may be necessary. Importantly, despite best medical therapy, surgery may be required in a proportion of patients. The future will likely see an array of new therapeutic options for those with ulcerative colitis with the potential for a more personalised treatment approach. ER -